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Abstract
Background: Recent epidemiologic, genetic, and molecular studies suggest infection and inflammation initiate
certain cancers, including cancers of the prostate. Over the past several years, our group has been studying how
mycoplasmas could possibly initiate and propagate cancers of the prostate. Specifically, Mycoplasma hyorhinis
encoded protein p37 was found to promote invasion of prostate cancer cells and cause changes in growth,
morphology and gene expression of these cells to a more aggressive phenotype. Moreover, we found that chronic
exposure of benign human prostate cells to M. hyorhinis resulted in significant phenotypic and karyotypic changes
that ultimately resulted in the malignant transformation of the benign cells. In this study, we set out to investigate
another potential link between mycoplasma and human prostate cancer.
Methods: We report the incidence of men with prostate cancer and benign prostatic hyperplasia (BPH) being
seropositive for M. hyorhinis. Antibodies to M. hyorhinis were surveyed by a novel indirect enzyme-linked
immunosorbent assay (ELISA) in serum samples collected from men presenting to an outpatient Urology clinic for
BPH (N = 105) or prostate cancer (N = 114) from 2006-2009.
Results: A seropositive rate of 36% in men with BPH and 52% in men with prostate cancer was reported, thus
leading us to speculate a possible connection between M. hyorhinis exposure with prostate cancer.
Conclusions: These results further support a potential exacerbating role for mycoplasma in the development of
prostate cancer.
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Background
Recent studies suggest infection and inflammation initiate
certain cancers including cancers of the prostate [1-5].
According to the American Cancer Society, approximately
20% of all worldwide cancers are caused by infections [6].
These infectious agents may directly induce tumorigenesis
through viral or bacterial protein products that have onco-
genic effects or indirectly through a local chronic and pro-
gressive inflammatory response [7-9]. There is a paucity of
information regarding the role of mucosal bacteria in
contributing to malignancies of the prostate. One class of
bacteria that is of particular interest is the Mollicutes.
Mycoplasmas (class Mollicutes) are tiny, pleomorphic,
wall-free, prokaryotic organisms that can reside either on
the eukaryotic cell membrane or inside the cell. They are
the smallest organisms (0.2-0.3 μm) capable of self-replica-
tion [10] with genomes of approximately 580-1200 kBp.
Several mycoplasmas have been well documented as
human pathogens [11,12], however, it is conceivable that
many mycoplasmal infections may go unidentified since
numerous species can grow for extended periods of time
in close interaction with mammalian cells without produ-
cing obvious cytopathic effects or noticeable symptoms.
A modern understanding of the latency of cancer and
the emerging role of microbes in carcinogenesis raises the
question of whether mycoplasmas can induce malignant
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[13,14]. Studies of leukemic patients in the mid-1960s
raised the possibility of an association between myco-
plasma infection and the development of leukemia [13].
Over the past several years much work has been devoted
to identifying a mechanism by which mycoplasmas can
transform cells. Specifically, our group reported that infec-
tion of benign human prostate cells, BPH-1, for 19 weeks
resulted in anchorage-independent growth, increased
migration and invasion, accumulation of chromosomal
aberrations and polysomy, and the ability to form xeno-
graft tumors in athymic mice. This was the first report
describing the capacity of M. hyorhinis infection to cause
the malignant transformation of benign human epithelial
cells [15]. Furthermore, our group demonstrated that cells
subjected to a single M. hyorhinis protein, p37, resulted in
increased proliferation, significant genomic changes, and
an enhanced invasive capability [16,17].
Working independently, several groups have detected
the M. hyorhinis p37 protein in cancer patients. The p37
protein was first described in an effort to identify human
cell antigens that elicit tumor-specific antibodies. Fareed
et al. [18] analyzed the immune response in a group of
cancer patients who were immunized intralymphatically
with tumor cell extracts. Sera samples from patients who
were in a state of tumor regression showed measurable
antibody titers against several antigens, including a
38-kDa protein. These antigens were not detected in
those patients whose tumors failed to regress. The
38 kDa antigen was later identified as a mycoplasmal pro-
tein from M. hyorhinis. The protein was designated as
p37 [19,20]. In this study, we developed an indirect
ELISA to investigate the presence of serum antibodies
(IgG and IgM) against M. hyorhinis p37 in men with
newly diagnosed localized prostate cancer.
Methods
Patient Serum Specimens
After Institutional Review Board approval and signed
informed consent, serum samples were prospectively col-
lected from 321 men presenting to the Department of
Urology University of Florida for evaluation of BPH or
prostate cancer from 2006-2009. Briefly, 5-ml of whole
blood was collected in a serum separating tube from each
subject. Within 30 minutes, the tube was placed in the
centrifuge and spun for 15 minutes at 2400 rpm as dic-
tated in our standard operating procedures of our depart-
mental tissue bank. Fifty microliter of serum was pipetted
into multiple 1-ml cryogenic vials, snap-frozen and
stored at -80°C for future use. Hospital records were
reviewed for demographic, clinical and pathologic data. A
total of 219 subjects (N = 114, BPH and N = 105, pros-
tate cancer) with adequate hospital records and banked
serum samples comprised the study cohort.
Expression and purification of recombinant p37
M. hyorhinis p37 (MH38-113) was expressed and purified
as previously described [16]. Briefly, plasmids were trans-
formed into BL21(DE3)pLysS E. coli cells. The transforma-
tion was used to inoculate 1-L LB media with 100 mg L21
ampicillin and cultured at 37°C until the OD 600 nm was
0.7-1.0. Cells were induced using 1 mL of 1M isopropyl b-
D-1 thiogalactopyranoside and allowed to express for
three hours. Cells were lysed by vortexing the pellet in
1/10 the original volume of 20 mmol/L phosphate buffer
(pH 7.8) followed by a sonication for three 15-second
cycles. The resulting crude cell lysate was centrifuged at
40,000 × g for 20 minutes at 4°C to remove cell debris.
The clear supernatant (soluble cellular extract) was sub-
jected to ion exchange chromatography using the Econo
System (Bio-Rad). A 5 mL Bio-Rad Econo-Pac S cation
exchange column was attached to the bottom of a 50 mL
Bio-Rad anion exchange Q column, and equilibrated with
20 mmol/L sodium phosphate buffer (pH 7.95) at a flow
rate of 2.5 mL/min. Approximately 125 mg of soluble cel-
lular extract were loaded on the column. The flow-
through containing M. hyorhinis p37 was adjusted to pH
6.1 with 2 mol/L acetic acid, and loaded on a 5 mL cation
exchanger, Bio-Rad Econo-Pac S cartridge, equilibrated
with 20 mmol/L sodium acetate, pH 6.1 (buffer A). The
column was washed with 5% buffer B [20 mmol/L sodium
acetate (pH 6.1), 1 mol/L NaCl] and the M. hyorhinis p37
protein was eluted with 15% buffer B. The eluted sample
was then concentrated using a Centriprep 10 spin column
(Millipore, Bedford MA). Purity was confirmed by 10%
SDS-PAGE stained with Coomassie Blue (Figure 1). Con-
centrations were calculated by absorbance at 280 nm
using a calculated extinction coefficient of 54,620 M
-1cm
-1.
Indirect ELISA
A 96-well plate was coated with 100 μlo fd i l u t e dM. hyor-
hinis p37 (0.5 μg/well). Plates were incubated for at least
one hour at room temperature. The plate was washed four
times with TBS/Tween 20 (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 5 mM MgCl2, 0.5 mM CaCl2, 0.05% (v/v)
Tween 20. Next, the plates were blocked with 300 μlo f
TBS/1% BSA and incubated for 1 hour. Again the plates
were washed as described above. Based on our preliminary
studies (data not shown), thawed human sera samples
were diluted 1/100 with TBS and 100 μl of each diluted
human sera were then added to the 96-well plate in dupli-
cate. Plates were incubated for another one hour at room
temperature. Plates were washed four times as described
previously followed by the addition of 100 μl of diluted
anti-human antibody (1/100) conjugated to alkaline phos-
phatase. Plates were incubated for one hour at room tem-
perature then washed again. Next, the plate was washed
once with TBS containing no Tween 20, and 100 μlo f
freshly made p-NPP in development buffer was added.
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control. The disaccharide, Gal1a1,3 Gal, is present in all
humans, and IgG antibodies to Gal1a1,3 Gal are found
to be present in high titers in the serum of every normal
individual, and are constantly produced throughout life
[21]. Gal1a1,3 Gal was purchased from Sigma Chemical
Co., St. Louis, Missouri, USA. Test serum samples were
also assayed with Gala1,3 Gal as the substrate (positive
control) coupled to bovine serum albumin (BSA). BSA
alone served as the negative control. Plates were read at
405 nm in a plate reader. All of the sera tested showed a
strong positive response against Gala1,3 Gal-BSA and no
response to BSA alone (data not shown).
Statistical analysis
We used the Wilcoxon rank-sum test to compare the
O.D. values and PSA values in the prostate cancer group
to those in the BPH group. Since we are testing the
hypothesis that the O.D. values and PSA values in the
prostate cancer group are higher than that in the BPH
group, all reported p-values are one-sided. The one-sided
Wilcoxon rank-sum test is also used to assess the corre-
lation between O.D. values and clinical parameters. We
defined a diagnostic test (positive indirect ELISA assay
vs. negative indirect ELISA assay) using a cutoff value of
O.D. selected to maximize the sum of the sensitivity and
specificity of the test [22]. All data analyses were per-
formed using SAS software version 9.1.3.
Results
Sera from a total of 219 subjects (N = 114, BPH and N
= 105, prostate cancer) comprised our study cohort.
The cohorts’ demographic, clinical and pathologic fea-
tures are summarized in Table 1. The two study groups
(BPH and prostate cancer) were well matched for age
and race. Serum PSAs were higher in the cancer group
versus the BPH group (5.7 +5.1 vs. 0.9+1.8, p < 0.0001).
Of the 105 subjects with prostate cancer, the majority of
subjects presented with low risk prostate cancer; clinical
T1c prostate cancer (69%), serum PSA <10 ng/ml (86%)
and Gleason score 3+3 = 6 (65%). A small percentage of
these subjects (n = 38) underwent a radical prostatect-
omy for definitive therapy. Table 2 describes clinico-
pathologic features of the prostatectomy cohort. Median
follow-up of our entire cohort was 18.1 months. In this
short follow-up, 5% of the patients experienced bio-
chemical recurrence.
Indirect ELISA assays were performed on all 219 sera
samples in duplicate. The median O.D. value for the BPH
group was 0.31 whereas the median O.D. value was 0.35 in
the prostate cancer group (p = 0.035). The distributions of
O. D. values are presented in a box plot (Figure 2).
Through further data analysis we determined an optimum
O.D. cut off value to distinguish a positive indirect ELISA
Figure 1 Purification of recombinant M. hyorhinis p37 protein
by affinity chromotography. M. hyorhinis p37 (MH38-113) was
expressed in E. coli and purified as described previously [16].
Sonicated cell lysate of E. coli was applied to a cobalt affinity
column, and the bound protein was eluted with 150 mM imidazole.
A total of 25 μg eluate was electrophoresed in a 12% SDS-PAGE gel,
and stained with Coomassie blue. M, Prestained BenchMark Protein
ladder (kDa); 1, purified recombinant protein. The arrow indicates
the position of the recombinant protein.
Table 1 Demographic and clinicopathologic
characteristics of study cohort
BPH Cancer
N = 114 N = 105
Median Age (range, y) 60 (30-86) 60 (41-79)
Race
White 73 (64) 72 (69)
African American 30 (26) 17 (16)
Other 11 (10) 16 (15)
Median Serum PSA (ng/ml) 0.9+1.8 5.7 ± 5.1
Clinical Stage
T1c n/a 74 (70%)
T2a n/a 26 (25%)
T2b n/a 1 (1%)
T2c n/a 2 (2%)
T3a/b n/a 1 (1%)
T2aNxM1 n/a 1 (1%)
Gleason Score
6 n/a 68 (65%)
7 n/a 23 (22%)
>7 n/a 14 (13%)
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> 0.348. Utilizing this O.D. cut off value, 41 out of the 114
(36%) BPH subjects and 55 of 105 (52%) prostate cancer
subjects had antibodies to M. hyorhinis p37 (p = 0.014)
(Table 3). Figure 3 depicts the sensitivity of this novel
indirect ELISA assay towards M. hyorhinis p37 antibodies.
The O.D. values were not significantly associated with
clinical stage of prostate cancer patients (p =0 . 3 9 ) .T h e
O.D. values of prostate cancer patients with Gleason score
7 or higher were significantly higher than that with Glea-
son score 6 (p = 0.016). Biochemical recurrence was not
associated with a positive ELISA assay (p >0 . 0 5 ) .
Discussion
In this study, we provide evidence supporting a potential
role for mycoplasma in the initiation and/or propagation
of human cancers. Fifty-two percent of men with pros-
tate cancer harbored antibodies to M. hyorhinis while
only thirty-six percent of men with the benign prostate
condition, BPH, were found to have antibodies to
M. hyorhinis (p = 0.014). If antibodies to M. hyorhinis
are present, then we assume that these individuals were
exposed to M. hyorhinis within their life time. This is
not unexpected since M. hyorhinis is a ubiquitous
organism. Other intriguing links between cancer and
M. hyorhinis exposure have been recently elucidated. A
group from Japan reported that 48% of tumors from
patients with gastric cancer were positive for M. hyorhi-
nis [23]. In addition, a study from China strongly sup-
ports a link between M. hyorhinis, p37 expression and
cancer. A monoclonal antibody that specifically recog-
nizes p37 was used to test for reactivity in over 500 par-
affin-embedded normal and diseased tissues. The results
indicated that 40-53% of gastric, esophageal, and colon
carcinoma samples were positive for reactivity with the
M. hyorhinis p37 monoclonal antibody [24].
Our laboratory has preliminary evidence linking M.
hyorhinis protein p37 to cancer initiation and/or pro-
gression [16,17]. Specifically we demonstrated that
recombinant p37 enhanced the invasiveness of two
prostate carcinoma and two melanoma cell lines in a
dose-dependent manner in vitro,b u td i dn o th a v ea
significant effect on tumor cell growth. These findings
could be completely blocked with a neutralizing anti-
body to M. hyorhinis p37 [16]. In a separate study,
recombinant M. hyorhinis p37 induced a more malig-
nant phenotype in prostate cancer cells PC-3 and
DU145 as demonstrated by significant nuclear enlarge-
ment, anaplasia, and increased migratory activity.
Furthermore, these cells showed differential expression
of genes involved in cell cycle, signal transduction and
Table 2 Demographic and clinicopathologic
characteristics of 38 study subjects who underwent
radical prostatectomy
Cancer
N=3 8
Median Age (range, y) 63 (47-72)
Race
White 24 (63)
African American 12 (32)
Other 2 (5)
Median Serum PSA (ng/ml) 9.2 ± 4.7
Pathologic Stage
pT2 31 (82%)
pT3a 3 (8%)
pT3b 4 (10%)
N0 36 (95%)
N1 2 (5%)
Gleason Score
6 19 (50%)
7 13 (34%)
>7 6 (16%)
Figure 2 Box plots of O.D. value detecting Mh y o r h i n i sserum
antibodies. The distributions of O. D. values are presented in a box
plot.
Table 3 Summary of serum Ig M.hyorhinis p37 antibody
detection by Indirect ELISA
-Ig Mh + Ig Mh p-value
Benign Patients (N = 114) 73/114 (64%) 41/114 (36%) 0.014
Cancer Patients (N = 105) 50/105 (48%) 55/105 (52%)
Figure 3 Detection limits of novel indirect ELISA for M.
hyorhinis serum antibodies. Varying concentrations of M. hyorhinis
antibodies were added to our indirect ELISA to illustrate the range
of detection.
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a strong association between M. hyorhinis p37 epitope
expression and cancer that is complex, probably
requiring a long latency period, and may be dependent
upon specific host factors.
Mycoplasmas are notorious for producing infections
that can persist for up to a year or longer [25]. The effects
of long-term exposure of mycoplasma on gene expression
in mammalian cells have been carefully studied [26]. Gene
expression changes were examined following infection of
human cervical and prostatic epithelial cells in vitro with a
panel of mycoplasmas. The changes in expression of 38
key cytokine genes were examined over a period of time
ranging from 12 hours to 36 weeks. The results indicated
that, even in the absence of apparent changes in cell
growth or cell morphology, mycoplasmal infections rapidly
altered the expression of many key genes, thus altering
numerous important biological functions within cells [26].
Over the past several years much work has been devoted
to identifying a mechanism by which mycoplasmas can
transform cells. The oncogenic potential of human myco-
plasmas, M. fermentans and M. penetrans, were studied
using cultured C3H mouse embryo cells [27]. Transforma-
tion with mycoplasma was a multistage process, with dis-
tinct phases in promotion and progression towards
malignancy. During initial mycoplasmal infection, the
effects were reversible (i.e., removal of the mycoplasma
restored normal cellular function). However, after chronic
infection, the transformation became irreversible. Thus,
mycoplasma-mediated oncogenesis had a long latency per-
iod and required a chronic persistent infection, as opposed
to the acute transformation induced by most oncogenic
viruses [26]. Because of this long latency, it is extremely
difficult to establish a link between mycoplasmas and can-
cer through an epidemiologic approach.
Our group has studied the oncogenic potential of M.
hyorhinis using cultured BPH-1, benign human prostate
cells. The immortalized BPH-1 cell line was derived from
primary cultures of benign prostatic epithelial cells by
introducing SV40T antigen [28] which inactivates both
p53 and Rb tumor suppressor genes. Thus we hypothe-
sized that further insult or stress (e.g., chronic mycoplas-
mal exposure) in these benign prostate cells may render
the benign cells susceptible to further genetic damage
and to progression along a pathway to malignancy. After
being exposed to M. hyorhinis for 19 weeks, BPH-1 cells
achieved anchorage-independent growth, increased
migration and invasion, accumulation of chromosomal
aberrations and polysomy and formed xenograft tumors
in athymic mice. Transformation with mycoplasma was a
multistage process, with distinct phases in promotion
and progression towards malignancy [15]. This novel cell
transformation model was critical in elucidating the
potential of chronic mycoplasmal exposure leading to the
development of prostate cancer. Though intriguing,
further work is needed to confirm and further explain
the role of M. hyorhinis in the development and propaga-
tion of human prostate cancer.
We report the development of the first indirect ELISA
assay for the detection of circulating M. hyorhinis antibo-
dies in human serum samples. Overall, M. hyorhinis anti-
body was detected in 44% of our cohort (36% in BPH and
52% in prostate cancer). The percent of IgG and IgM
antibodies within the entire pool of antibodies were not
determined, neither were antibody titers, however, we
did find this system of detecting M. hyorhinis antibodies
to be reliable and simple, thus allowing further evaluation
of this assay in subjects with prostate cancer.
Overall this study provides strong evidence that humans
are exposed to M. hyorhinis and such exposure may be
associated with the development of certain cancers. We
recognize that numerous limitations are evident in the
current study. First, this is a small, highly selected cohort
and thus may not represent the average BPH or prostate
cancer patient. Second, confirmation of M. hyorhinis
within the prostate via immunohistochemical staining or a
similar assay was not performed due to limitations of
high-quality antibodies directed at M. hyorhinis.T h i r d ,t h e
association between mycoplasma and prostate cancer is
complex and may require a long latency period, a specific
set of host attributes, or possibly exposure to a particular
strain of mycoplasma, none of these have been clearly
identified. Fourth, we do not believe M. hyorhinis itself
causes malignant transformation, but when present it may
further stress cells that have the propensity to become
malignant as was evident in our preclinical study [15].
Fifth, our control group was comprised of men with BPH,
a benign overgrowth of the prostate. Though it would be
ideal to have as a control men without this benign over-
growth of the prostate it is not feasible seeing that the
majority of elderly men will have BPH.
We have demonstrated an increased rate of seropositiv-
ity to M. hyorhinis in men with prostate cancer (52%)
compared to men with BPH (36%) presenting to an out-
patient Urology clinic, thus providing the first correlation
of mycoplasmal exposure and prostate cancer. Though a
significant percentage of men with BPH harbored antibo-
dies to M. hyorhinis p37, we still believe we have a valid
hypothesis. First, M. hyorhinis is ubiquitously found in
the environment. Second, we believe that prostatic tissue
m a yb ee x p o s e dt oM. hyorhinis, which can cause a
chronic inflammatory milieu leading to cellular changes.
This effect may be instigated by the cell surface protein
p37 directly. These cellular changes, when coupled with
other cellular stressors, can induce malignant transfor-
mation. Thus, it is not surprising to find M. hyorhinis
in significant proportion of subjects with a benign
condition.
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Our current findings coupled with our previous findings
of how mycoplasma can transform benign prostatic cells
have led us to hypothesize that mycoplasmal exposure
may be linked to the initiation and propagation of some
prostate cancers. Further epidemiologic studies into this
phenomenon are required, but the idea that mycoplas-
mas can exacerbate, or perhaps even initiate human
prostate malignancy may stimulate new thinking on
how we prevent, diagnose and treat prostate cancers.
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